In addition, CHK2 germline mutations and rare somatic mutations have been detected with high incidence in a number of familial cancers in humans, including prostate, breast, ovarian, thyroid, kidney, colorectal and bladder cancers, and leukemias [43, 44], suggesting that CHK2 may be a good target in cancer therapy. The gene discussed is CHEK2; the disease is hereditary cancer.